reposted from: http://www.bmj.com/content/341/bmj.c7326.extract
wrote about the Peter Rothwell paper at Cancer Research UK.
The BMJ Editor wrote:
Finally, aspirin. At the close of 2010, the Lancet published a meta-analysis of individual patient data from randomised controlled trials (Lancet 2010, doi:10.1016/S0140-6736(10)62110-1). It found a 21% reduction in deaths from cancer in people who took aspirin for almost six years. The news that aspirin prevented cancer hit the headlines, and no doubt prescriptions of aspirin in healthy people over a certain age are now on their way up. We asked Paul Moayyedi and Janusz Jankowski to look at the new data. In their editorial (doi:10.1136/bmj.c7326) they conclude that, with a number needed to treat of 200 but a 50% increased risk of serious gastrointestinal and extracranial bleeding, it is not clear that the benefits outweigh the risks, even when factoring in the cardioprotective effects of aspirin. Have a good, and rational, 2011.